Leerink Partnrs Has Pessimistic View of VYGR FY2024 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Equities researchers at Leerink Partnrs lowered their FY2024 earnings per share estimates for Voyager Therapeutics in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst L. Nsongo now anticipates that the company will earn ($0.66) per share for the year, down from their previous forecast of ($0.44). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.27) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at ($0.45) EPS.

A number of other brokerages have also weighed in on VYGR. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Sunday, November 10th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday. Wedbush lowered their target price on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Leerink Partners assumed coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price for the company. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a research note on Thursday. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Voyager Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock opened at $5.64 on Friday. The stock has a fifty day moving average price of $6.62 and a two-hundred day moving average price of $7.50. Voyager Therapeutics has a 52-week low of $5.59 and a 52-week high of $11.72. The firm has a market capitalization of $307.55 million, a P/E ratio of 7.94 and a beta of 0.89.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its holdings in Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after buying an additional 37,398 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of Voyager Therapeutics during the 3rd quarter valued at about $6,192,000. Verition Fund Management LLC bought a new position in shares of Voyager Therapeutics during the 3rd quarter valued at about $216,000. BNP Paribas Financial Markets lifted its holdings in shares of Voyager Therapeutics by 30.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 49,235 shares of the company’s stock valued at $288,000 after purchasing an additional 11,516 shares in the last quarter. Finally, FMR LLC lifted its holdings in shares of Voyager Therapeutics by 26.9% during the 3rd quarter. FMR LLC now owns 92,498 shares of the company’s stock valued at $541,000 after purchasing an additional 19,622 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Insiders Place Their Bets

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.53% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.